Share Name Share Symbol Market Type
Merck and Co Inc NYSE:MRK NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 78.17 995 10:26:34

Merck's Cancer Drug Keytruda Meets Primary Endpoint in Phase 3 Trial

08/04/2021 12:31pm

Dow Jones News

Merck (NYSE:MRK)
Historical Stock Chart

From Mar 2021 to May 2021

Click Here for more Merck Charts.

By Matt Grossman


Merck & Co. Inc.'s Keytruda drug met the primary endpoint of a Phase 3 trial to evaluate its use in treating an additional form of cancer, the Kenilworth, N.J.-based pharmaceutical company said Thursday.

The trial evaluated Keytruda's use as an adjuvant treatment for people with renal cell carcinoma following a nephrectomy, or a nephrectomy and the resection of metastatic lesions. Nephrectomy is the removal of a kidney. In the trial, which included 950 patients, subjects received either Keytruda or a placebo.

Keytruda led to a meaningful improvement in disease-free survival compared with the placebo in the trial, Merck said. Researchers will continue to evaluate overall survival among the patients in the trial.

Dr. Roy Baynes, Merck Research Laboratories' chief medical officer, said the company would share detailed results from the trial with regulators as soon as possible.

Keytruda, or pembrolizumab, has already been approved in the U.S. for roles in treating other forms of cancer.


Write to Matt Grossman at


(END) Dow Jones Newswires

April 08, 2021 07:16 ET (11:16 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Merck Chart

1 Year Merck Chart

1 Month Merck Chart

1 Month Merck Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210511 09:42:50